Literature DB >> 27625351

Intranasal Opioid Administration in Rhesus Monkeys: PET Imaging and Antinociception.

Phillip A Saccone1, Angela M Lindsey2, Robert A Koeppe2, Kathy A Zelenock2, Xia Shao2, Phillip Sherman2, Carole A Quesada2, James H Woods2, Peter J H Scott2.   

Abstract

The goal of this study was to evaluate the effects of intranasally administered opioids in rhesus monkeys using the tail-withdrawal assay, and to correlate these effects with measures of receptor occupancy using positron emission tomography (PET) imaging. Initial experiments characterized the antinociceptive effects of intranasal (IN) fentanyl and buprenorphine relative to intramuscular (IM) injection. Fentanyl (0.010-0.032 mg/kg) and buprenorphine (0.1-1.0 mg/kg) produced dose-dependent increases in tail-withdrawal latency that did not differ between routes of delivery. The second experiment compared the ability of IN and intravenous (IV) naloxone (NLX) to block the antinociceptive effects IV fentanyl, and to measure receptor occupancy at equipotent doses of NLX using PET imaging. IN and IV NLX (0.0032-0.032 mg/kg) produced dose-dependent decreases in fentanyl-induced antinociception. Again, there was no difference observed in overall potency between routes. PET imaging showed that IV and IN NLX produced similar decreases in receptor occupancy as measured by [11C]carfentanil blocking, although there was a trend for IV NLX to produce marginally greater occupancy changes. This study validated the first procedures to evaluate the IN effects of opioids in rhesus monkeys.
Copyright © 2016 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27625351      PMCID: PMC5074481          DOI: 10.1124/jpet.116.235192

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  39 in total

1.  Population pharmacokinetics of intravenous, intramuscular, and intranasal naloxone in human volunteers.

Authors:  Jonathonm Dowling; Geoffrey K Isbister; Carl M J Kirkpatrick; Daya Naidoo; Andis Graudins
Journal:  Ther Drug Monit       Date:  2008-08       Impact factor: 3.681

Review 2.  Intranasal drug delivery: how, why and what for?

Authors:  Anaísa Pires; Ana Fortuna; Gilberto Alves; Amílcar Falcão
Journal:  J Pharm Pharm Sci       Date:  2009       Impact factor: 2.327

Review 3.  The blood-brain barrier and nasal drug delivery to the central nervous system.

Authors:  Marcel Menon Miyake; Benjamin S Bleier
Journal:  Am J Rhinol Allergy       Date:  2015 Mar-Apr       Impact factor: 2.467

4.  Efficacy of intranasal naloxone as a needleless alternative for treatment of opioid overdose in the prehospital setting.

Authors:  Erik D Barton; Christopher B Colwell; Timothy Wolfe; Dave Fosnocht; Craig Gravitz; Tamara Bryan; Will Dunn; Jeff Benson; Jeff Bailey
Journal:  J Emerg Med       Date:  2005-10       Impact factor: 1.484

5.  Intranasal naloxone administration by police first responders is associated with decreased opioid overdose deaths.

Authors:  Jessica Rando; Derek Broering; James E Olson; Catherine Marco; Stephen B Evans
Journal:  Am J Emerg Med       Date:  2015-05-29       Impact factor: 2.469

6.  Apparent pA2 analysis on the respiratory depressant effects of alfentanil, etonitazene, ethylketocyclazocine (EKC) and Mr2033 in rhesus monkeys.

Authors:  E R Butelman; C P France; J H Woods
Journal:  J Pharmacol Exp Ther       Date:  1993-01       Impact factor: 4.030

7.  Distribution of olfactory epithelium in the primate nasal cavity: are microsmia and macrosmia valid morphological concepts?

Authors:  Timothy D Smith; Kunwar P Bhatnagar; Praphul Tuladhar; Annie M Burrows
Journal:  Anat Rec A Discov Mol Cell Evol Biol       Date:  2004-11

8.  A tail withdrawal procedure for assessing analgesic activity in rhesus monkeys.

Authors:  L A Dykstra; J H Woods
Journal:  J Pharmacol Methods       Date:  1986-06

9.  Early pharmacokinetics of nasal fentanyl: is there a significant arterio-venous difference?

Authors:  Kristin Moksnes; Olav M Fredheim; Pål Klepstad; Stein Kaasa; Anders Angelsen; Turid Nilsen; Ola Dale
Journal:  Eur J Clin Pharmacol       Date:  2008-01-06       Impact factor: 2.953

10.  Intranasal administration of drugs.

Authors:  Mandy Scheibe; Christopher Bethge; Martin Witt; Thomas Hummel
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2008-06
View more
  10 in total

1.  Pharmacokinetics of a Long-lasting, Highly Concentrated Buprenorphine Solution after Subcutaneous Administration in Rhesus Macaques (Macaca mulatta).

Authors:  Alexis L Mackiewicz; Gregory W Salyards; Heather K Knych; Ashley E Hill; Kari L Christe
Journal:  J Am Assoc Lab Anim Sci       Date:  2019-06-21       Impact factor: 1.232

2.  Intranasal naloxone rapidly occupies brain mu-opioid receptors in human subjects.

Authors:  Jarkko Johansson; Jussi Hirvonen; Zsófia Lovró; Laura Ekblad; Valtteri Kaasinen; Olli Rajasilta; Semi Helin; Jouni Tuisku; Saija Sirén; Mirka Pennanen; Arvind Agrawal; Roger Crystal; Petri J Vainio; Hannu Alho; Mika Scheinin
Journal:  Neuropsychopharmacology       Date:  2019-03-13       Impact factor: 7.853

3.  Indirect SPECT Imaging Evaluation for Possible Nose-to-Brain Drug Delivery Using a Compound with Poor Blood-Brain Barrier Permeability in Mice.

Authors:  Asuka Mizutani; Masato Kobayashi; Makoto Ohuchi; Keita Sasaki; Yuka Muranaka; Yusuke Torikai; Shota Fukakusa; Chie Suzuki; Ryuichi Nishii; Shunji Haruta; Yasuhiro Magata; Keiichi Kawai
Journal:  Pharmaceutics       Date:  2022-05-10       Impact factor: 6.525

Review 4.  Fentanyls continue to replace heroin in the drug arena: the cases of ocfentanil and carfentanil.

Authors:  Nektaria Misailidi; Ioannis Papoutsis; Panagiota Nikolaou; Artemisia Dona; Chara Spiliopoulou; Sotiris Athanaselis
Journal:  Forensic Toxicol       Date:  2017-08-18       Impact factor: 4.096

5.  Naloxone's dose-dependent displacement of [11C]carfentanil and duration of receptor occupancy in the rat brain.

Authors:  Yeona Kang; Kelly A O'Conor; Andrew C Kelleher; Joseph Ramsey; Abolghasem Bakhoda; Seth M Eisenberg; Wenjing Zhao; Tyler Stodden; Torben D Pearson; Min Guo; Nina Brown; Jeih-San Liow; Joanna S Fowler; Sung Won Kim; Nora D Volkow
Journal:  Sci Rep       Date:  2022-04-19       Impact factor: 4.996

Review 6.  New idea to promote the clinical applications of stem cells or their extracellular vesicles in central nervous system disorders: Combining with intranasal delivery.

Authors:  Yaosheng Li; Honghui Wu; Xinchi Jiang; Yunfei Dong; Juanjuan Zheng; Jianqing Gao
Journal:  Acta Pharm Sin B       Date:  2022-04-07       Impact factor: 14.903

7.  Higher naloxone dosing in a quantitative systems pharmacology model that predicts naloxone-fentanyl competition at the opioid mu receptor level.

Authors:  Ronald B Moss; Meghan McCabe Pryor; Rebecca Baillie; Katherine Kudrycki; Christina Friedrich; Mike Reed; Dennis J Carlo
Journal:  PLoS One       Date:  2020-06-16       Impact factor: 3.240

8.  Mass Spectrometric Imaging of the Brain Demonstrates the Regional Displacement of 6-Monoacetylmorphine by Naloxone.

Authors:  Belin G Teklezgi; Annapurna Pamreddy; Sphamandla Ntshangase; Sipho Mdanda; Sanil D Singh; Nirmala D Gopal; Tricia Naicker; Hendrik G Kruger; Thavendran Govender; Sooraj Baijnath
Journal:  ACS Omega       Date:  2020-05-27

9.  Pharmacological Characterization of Low-to-Moderate Affinity Opioid Receptor Agonists and Brain Imaging with 18F-Labeled Derivatives in Rats.

Authors:  Julian Ott; Mona M Spilhaug; Simone Maschauer; Waqas Rafique; Jimmy E Jakobsson; Karoline Hartvig; Harald Hübner; Peter Gmeiner; Olaf Prante; Patrick J Riss
Journal:  J Med Chem       Date:  2020-08-17       Impact factor: 7.446

10.  The Effects of Intramuscular Naloxone Dose on Mu Receptor Displacement of Carfentanil in Rhesus Monkeys.

Authors:  Peter J H Scott; Robert A Koeppe; Xia Shao; Melissa E Rodnick; Alexandra R Sowa; Bradford D Henderson; Jenelle Stauff; Phillip S Sherman; Janna Arteaga; Dennis J Carlo; Ronald B Moss
Journal:  Molecules       Date:  2020-03-17       Impact factor: 4.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.